Todays Report: The Stevens First Principles Investment Advisors reaches $332,000 position of Edwards Lifesciences Corp. (EW)

The Stevens First Principles Investment Advisors reaches $332,000 position  of Edwards Lifesciences Corp. (EW)

Stevens First Principles Investment Advisors cut its stake in Edwards Lifesciences Corp. (NYSE:EW) by 4.3% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 3,326 shares of the medical research company’s stock after selling 150 shares during the period. Stevens First Principles Investment Advisors’ holdings in Edwards Lifesciences Corp. were worth $332,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the company. BlackRock Institutional Trust Company N.A. boosted its stake in Edwards Lifesciences Corp. by 0.3% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 5,451,618 shares of the medical research company’s stock valued at $480,887,000 after buying an additional 14,400 shares during the period. BlackRock Group LTD boosted its stake in Edwards Lifesciences Corp. by 0.5% in the first quarter. BlackRock Group LTD now owns 2,017,058 shares of the medical research company’s stock valued at $177,926,000 after buying an additional 10,581 shares during the period. Geode Capital Management LLC boosted its stake in Edwards Lifesciences Corp. by 3.6% in the first quarter. Geode Capital Management LLC now owns 1,887,308 shares of the medical research company’s stock valued at $166,168,000 after buying an additional 66,142 shares during the period. Renaissance Technologies LLC boosted its stake in Edwards Lifesciences Corp. by 50.7% in the first quarter. Renaissance Technologies LLC now owns 1,665,800 shares of the medical research company’s stock valued at $146,940,000 after buying an additional 560,700 shares during the period. Finally, American Century Companies Inc. boosted its stake in Edwards Lifesciences Corp. by 83.1% in the second quarter. American Century Companies Inc. now owns 1,423,750 shares of the medical research company’s stock valued at $141,991,000 after buying an additional 646,142 shares during the period. Institutional investors and hedge funds own 84.09% of the company’s stock.

Shares of Edwards Lifesciences Corp. (NYSE:EW) traded down 0.09% on Friday, reaching $119.61. 330,679 shares of the company were exchanged. The company has a market capitalization of $25.46 billion, a price-to-earnings ratio of 49.43 and a beta of 0.56. Edwards Lifesciences Corp. has a 52 week low of $71.93 and a 52 week high of $121.73. The company’s 50-day moving average is $117.36 and its 200-day moving average is $106.97.

Edwards Lifesciences Corp. (NYSE:EW) last released its quarterly earnings results on Tuesday, July 26th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.70 by $0.06. The company had revenue of $759.30 million for the quarter, compared to the consensus estimate of $724.26 million. Edwards Lifesciences Corp. had a net margin of 19.26% and a return on equity of 23.72%. Edwards Lifesciences Corp.’s revenue was up 23.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.57 earnings per share. On average, equities analysts expect that Edwards Lifesciences Corp. will post $2.88 EPS for the current fiscal year.

A number of equities analysts recently commented on the stock. Zacks Investment Research cut shares of Edwards Lifesciences Corp. from a “hold” rating to a “sell” rating in a research report on Tuesday, July 12th. Canaccord Genuity lifted their target price on shares of Edwards Lifesciences Corp. from $132.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, July 27th. Evercore ISI reiterated a “hold” rating and issued a $115.00 target price on shares of Edwards Lifesciences Corp. in a research report on Friday, August 19th. BMO Capital Markets reiterated a “buy” rating and issued a $120.00 target price on shares of Edwards Lifesciences Corp. in a research report on Wednesday, July 27th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating and issued a $130.00 target price on shares of Edwards Lifesciences Corp. in a research report on Thursday, July 28th. One research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $118.13.

In related news, Director Schack Wesley W. Von sold 6,000 shares of the company’s stock in a transaction on Monday, August 1st. The shares were sold at an average price of $113.98, for a total transaction of $683,880.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Huimin Wang sold 13,650 shares of the company’s stock in a transaction on Wednesday, October 5th. The shares were sold at an average price of $120.04, for a total transaction of $1,638,546.00. The disclosure for this sale can be found here. Corporate insiders own 2.37% of the company’s stock.

About Edwards Lifesciences Corp.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

Related posts

Leave a Comment